Compare WATT & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | CLRB |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.8M |
| IPO Year | 2014 | N/A |
| Metric | WATT | CLRB |
|---|---|---|
| Price | $5.97 | $3.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.5K | ★ 59.6K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $509.64 | N/A |
| Revenue Next Year | $210.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | N/A |
| 52 Week Low | $3.67 | $2.71 |
| 52 Week High | $81.00 | $41.70 |
| Indicator | WATT | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 61.42 |
| Support Level | $5.92 | $3.30 |
| Resistance Level | $6.77 | $3.15 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 14.18 | 97.94 |
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.